Видео

Hello, thanks for the lesson, How can I edit and change data in the Google file, Looks like you need permission to edit thanks

Hey man, I really appreciate this video, really the most practical describing a proper DCF specific for biotech industry. I am doing my finance msc and my thesis is about valuing a biotech. I will build my model based on this video, not entirely but heavily inspired. I cannot cite you tho since it's a youtube video. By chance, do you have any relevant literature that describes this process the way you just did? Or anything academic that you or someone else wrote regarding this specific area?

this video series is extremely helpful. pharmd soon to be md, but have always been involved in biotech speculating, I call it that instead of investing because i have no finance background. have been building models for phase 3 drugs for prerevanue single drug companies and have been pretty lucky so far. started with a company called AVEO, and made out alright after they were bought by LG chem i think last year. they had a drug which went though the entire phase 3 and failed at the finish line, and then changed their indication to be specific for pdl-1 RCC, which did well in their subgorup analysis of their tivo-2 trials. I was able to made a somewhat robust model and use montey carlo to fill in the gaps before a lot of the trial info was released which proved valid. now i got this company that i hate, RIGL which is like a 3 drug post revanue company and im trying to figure out when to dump the stock coz i think a buyout is comming now that theyre somewhat profitable. really like their drug on the market, we had a few patients on it in a clinic I was at. I really wonder how finance bros even begin to wrap their head around place in therapy and indications lol. hoping thats an edge. really interesting drug if youre into pharmacology: Fostamatinib, sold under the name Tavalisse, which is kind of its own catagory of drug right now, approved only for ITP but some really interesting applications. feel like most of the money pharma makes is at heme onc clinics since its so many one off diseases and life determining treatments. thanks for uploading all this, there was nothing like this on youtube 5 years ago when i looked, thanks richard

26:00 how the hell do you build a company when they want to track you for 5 years before they commit check

Great examples, very helpful

Would love to see a close out video on recent news about Aducanumab and also any thoughts you have on Lecanemab's approval and prosects.

Awesome video! Cheers from Brazil.

Would you be so kind to valuate Cassava Sciences. Small Biotech in the Alzheimer's Space. Thx.

💯💯💯

Thank you for making.

Nobody is holding a short position for years...misleading video. You absolutely can short biotechnology successfully because most of these companies are unprofitable and in debt, but it must be a quick trade.

Cereno Scientific NeXT ❤

Yes, content level is beyond imagination!

Such a great videos! Thank you so much for sharing your knowledge! Hope you will not abandon this channel

This is a supremely helpful video. Thank you! We hope you come back ❤

Why is this old information still on here?!

Thank you so much for these amazing series! Happily subscribed.

These videos are amazingly informative, thank you so deeply for your efforts and generosity

What the heck man. This stuff is great, I really don’t get the lack of attention to this channel.

You need to keep this channel going, I’m not new to trading but the things you teach are excellent I learn a lot from you! It’s sad that people don’t want to learn they just want easy money and ad revenue dictates that by giving a great channel less views… But you are a great resource and I hope you keep the content going.

Great stuff would like to see the next part

High quality content

Why’d you stop making videos

Underwhelming talk. Very generic and useless honestly

What tool did you use for the model?

Very helpful video, thank you! Do you know of any good resources to help develop assumptions to project any post-approval R&D costs?

in hindsight the downturn was caused by a lot of small early clinical to preclinical start up going public, receiving mountains of cash from braindead investors then those investors crying after not following the golden rule of biotech/pharma "90% of drugs fail to get through the clinic" So it doesn't seem like to me biotech had the problem , the problem are venture capital bros who don't understand what they are investing in because they played they were lucky on the stock market or born into money, or they went to an ivy league school and people gave them money under assumption they were intelligent. The problem was too many stupid people had too much money, and we will see the same exact behavior with AI start ups and it will be even more volatile because they don't have to go through anything like the FDA to get to market. part of our problem is a problem of culture and assuming a lot of money means a person is intelligent or we will keep repeating the same mistakes with every tech sector until we get some better investors, because most won't say it , but most of them want to be the next Martin Shkreli minus the prison.

This case study was fascinating, thanks!

Many thanks Man!!

this video prevent degen from turning into serial killer.

As someone who is an early employee of a startup, this video was significantly helpful. Thank you.

Question : is there a general rule on whether to start with incidence or with prevalence?

Do you have any thoughts about Takeda's Qdenga vaccine?

Thank you for this truly great deep dive into some promising advances. Hoping to hear more about what you think going forward.

Great content, thank you Richard!

1 year later GRPH remains at $2.56

Hey, awesome video! I was trying out a valuation for a small biotech and realized that I was having some trouble finding the list price for drugs and information on drug penetration for benchmarking. Is there a database where we can find these values or are they provided in one of the financial statement documents? I apologize if this is a really basic question - my background is in science so I am a bit unfamiliar with the more financial/ cost projection side of things. Thanks in advance!

Legend. Best channel.

Legend. Best channel ever.

Awesome man, thank you so much for this

great series. I was alarmed, when you mentioned Seres. At first I thought, you are going to talk about Syros (where I am invested in). But I am not english native speaker so I just got it wrong. However I would appreciate your 2 cents regarding Syros Pharmaceuticals (Flagship Pioneering is Co-Founder here).

Great content. Would love to see you cover Argenx

Thank you for this. Question... I often use operating cash flow for a non-revenue generating companies like biotech. Would that be a reasonable surrogate? I imagine using the income statement might factor in other non-recurring factors? Thanks!

Extremely well-structured content. Also, really really legit approach to the analysis. Thanks a lot! Got lucky finding this

Great overview. Thank you

Great introduction. Looking forward to the additional videos

Your content is awesome plainly simple

Great summary. Need more videos! 🎉

Great details 👍

Awesome content Richard! Keep the analysis videos coming :-)